THERAPY DOSSIER · th-bd013622fafb

KN38-7271

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: KN38-7271
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23069763 ↗2012Reported benefit

Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia.

RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-DawleyMaleDose dependent effect reported; numerical doses not stated…Applied before, during and after occlusion; also effective when delayed up to 6…

Model: Transient focal cerebral ischaemia by endothelin induced middle cerebral artery occlusion

KN38-7271 gave significant dose dependent and long lasting reduction in cortical lesion size and improved severe motor deficits, including with 6 h delayed dosing.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…